<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131738</url>
  </required_header>
  <id_info>
    <org_study_id>201911012</org_study_id>
    <nct_id>NCT04131738</nct_id>
  </id_info>
  <brief_title>Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation</brief_title>
  <official_title>A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, the investigators will begin to explore the possibility that, as in mice,&#xD;
      JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate&#xD;
      graft-versus-host-disease (GVHD) while retaining engraftment and Graft-versus-Leukemia (GVL).&#xD;
      Both preclinical and clinical data suggest that inhibition of IFNy and IL-6, directly and&#xD;
      using downstream JAK Inhibitors, may be an effective strategy to decrease toxicities and&#xD;
      improve disease control for patients undergoing Allogeneic HSCT. Baricitinib, as a JAK1/2&#xD;
      inhibitor, has shown superiority to other JAK inhibitors in preclinical GVHD models. The&#xD;
      purpose of this phase I clinical trial is to determine the safety of baricitinib with HSCT&#xD;
      measured by the effect on engraftment and grade III-IV acute graft-versus-host-disease&#xD;
      (aGVHD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>If all 3 patients in the safety lead-in for the 2 mg dose level achieve engraftment, 9 additional patients will be enrolled at that dose level.&#xD;
If all 3 patients in the safety lead-in for the 4 mg dose level achieve engraftment, 9 additional patients will be enrolled at that dose level.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of graft failure</measure>
    <time_frame>28 days post transplant</time_frame>
    <description>-Failure to engraft will be defined as failure to achieve absolute neutrophil count &gt; 500 for 3 days by Day 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of grade III-IV acute GVHD</measure>
    <time_frame>Day 100</time_frame>
    <description>-Acute GVHD will be assessed using MAGIC criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>Day 180</time_frame>
    <description>-Death that results from a transplant procedure-related complication (e.g. infection, organ failure, hemorrhage, GVHD) rather than from relapse of the underlying disease or an unrelated cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Graft-versus-host-disease</condition>
  <condition>Graft Vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Baricitinib 2 mg Dose Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 0 the allograft will be infused per standard institutional practice&#xD;
Baricitinib will be administered PO at a starting dose of 2 mg daily from Day -3 to Day 100&#xD;
After Day 100, for patients already dose reduced to 2 mg daily, reduce baricitinib to 2 mg every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib 4 mg Dose Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 0 the allograft will be infused per standard institutional practice&#xD;
Baricitinib will be administered PO at a starting dose of 4 mg daily from Day -3 to Day 100&#xD;
After Day 100, for patients at a dose of 4 mg daily, reduce baricitinib to 2 mg daily for one month, then every other day for one month or 1 mg daily for one month (depending on drug supply) then discontinue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Baricitinib may be taken without regard to food. It should be taken at the same time every day.</description>
    <arm_group_label>Baricitinib 2 mg Dose Level</arm_group_label>
    <arm_group_label>Baricitinib 4 mg Dose Level</arm_group_label>
    <other_name>Olumiant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet the following criteria within 30 days prior to Day 0 unless otherwise&#xD;
        noted.&#xD;
&#xD;
          -  Diagnosis of a hematological malignancy listed below:&#xD;
&#xD;
               -  Acute myelogenous leukemia (AML) in complete morphological remission (based on&#xD;
                  IWG Criteria).&#xD;
&#xD;
               -  Acute lymphocytic leukemia (ALL) in complete morphological remission (MRD&#xD;
                  negative, based on IWG Criteria).&#xD;
&#xD;
               -  Myelodysplastic syndrome with less than 10% blasts in bone marrow.&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater complete&#xD;
                  or partial remission.&#xD;
&#xD;
          -  Planned treatment is myeloablative or reduced intensity conditioning followed by&#xD;
             peripheral blood HLA matched donor transplantation&#xD;
&#xD;
          -  Available HLA-identical donor who meets the following criteria:&#xD;
&#xD;
               -  At least 18 years of age.&#xD;
&#xD;
               -  HLA-identical donor/recipient match by high-resolution typing per institutional&#xD;
                  standards.&#xD;
&#xD;
               -  In the investigator's opinion, is in general good health, and medically able to&#xD;
                  tolerate leukapheresis required for harvesting HSC.&#xD;
&#xD;
               -  No active hepatitis.&#xD;
&#xD;
               -  Negative for HTLV and HIV.&#xD;
&#xD;
               -  Not pregnant.&#xD;
&#xD;
               -  Donor selection will be in compliance with institutional standards&#xD;
&#xD;
               -  Safety Lead-In Phase: For the first three patients at each dose level, related&#xD;
                  donors must consent to a second product collection should it prove necessary.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
          -  Adequate organ function as defined below:&#xD;
&#xD;
               -  Total bilirubin must be within normal range at baseline.&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤ 3.0 x IULN.&#xD;
&#xD;
               -  Estimated creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault Formula.&#xD;
&#xD;
               -  Oxygen saturation ≥ 90% on room air.&#xD;
&#xD;
               -  LVEF ≥ 40%.&#xD;
&#xD;
               -  FEV1 and FVC ≥ 40% predicted, DLCOc ≥ 40% predicted. If DLCO is &lt; 40%, patients&#xD;
                  will still be considered eligible if deemed safe after a pulmonary evaluation.&#xD;
&#xD;
          -  At least 18 years of age at the time of study registration&#xD;
&#xD;
          -  Able to understand and willing to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
          -  Must be able to receive GVHD prophylaxis with tacrolimus, mini-methotrexate with or&#xD;
             without ATG or post transplant Cy with MMF and tacrolimus as outlined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Must not have undergone a prior allogeneic donor (related, unrelated, or cord)&#xD;
             transplant. Prior autologous transplant is not exclusionary.&#xD;
&#xD;
          -  Known HIV or active hepatitis B or C infection.&#xD;
&#xD;
          -  Known latent tuberculosis infection, or at high risk for latent TB infection, or a&#xD;
             positive t-spot tuberculosis test&#xD;
&#xD;
          -  Known hypersensitivity to one or more of the study agents, including baricitinib.&#xD;
&#xD;
          -  Must not have myelofibrosis or other disease known to prolong neutrophil engraftment&#xD;
             to &gt; 35 days after transplant.&#xD;
&#xD;
          -  Currently receiving or has received any investigational drugs within the 14 days prior&#xD;
             to the first dose of study drug (Day -3).&#xD;
&#xD;
          -  Pregnant and/or breastfeeding.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, autoimmune disease, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, unstable cardiac arrhythmias, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements.&#xD;
&#xD;
          -  Immunosuppressive doses of steroids. Subjects with steroids for adrenal insufficiency&#xD;
             will not be excluded.&#xD;
&#xD;
          -  History of unprovoked thrombosis or known thrombophilia. Provoked and/or superficial&#xD;
             DVTs are eligible provided they are treated and resolved at the time of screening.&#xD;
&#xD;
          -  Recent (less than 1 year from screening) myocardial infarction or embolic stroke&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Schroeder, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark A Schroeder, M.D.</last_name>
    <phone>314-454-8304</phone>
    <email>markschroeder@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark A Schroeder, M.d.</last_name>
      <phone>314-454-8304</phone>
      <email>markschroeder@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Mark A Schroeder, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordan Atkins, M.D., M.P.H.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Himachandana Atluri, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille Abboud, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Cashen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John F DiPersio, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Fehniger, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Ferraro, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armin Ghobadi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meagan Jacoby, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iskra Pusic, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Stockerl-Goldstein, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Uy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi Vij, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathew Walter, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Wartman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Welch, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Westervelt, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Gao, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramzi Abboud, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacob Choi, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

